Meril Introduces Myval Octapro THV to Advance Cardiac Treatment at Global Conferences

Meril Champions Heart Health Innovation

Meril Life Sciences has taken a significant step forward in cardiac care with the unveiling of its newest innovation, the Myval Octapro THV (Transcatheter Heart Valve). This state-of-the-art device is set to be launched at two prestigious global medical conferences: GISE 2024 in India and PCR London Valves 2024. As a leader in advanced cardiovascular and structural heart solutions, Meril continues to push the boundaries of technology, emphasizing its commitment to improving patient outcomes and supporting healthcare providers worldwide.

Commitment to Innovation

Since its inception, Meril has been at the forefront of developing next-generation solutions that aim to redefine the landscape of cardiac therapies. The Myval Octapro THV represents the latest evolution in the Myval series, showcasing Meril's dedication to enhancing transcatheter aortic valve replacement (TAVR) technologies. This innovative device is characterized by a shorter frame for improved operator control and a predictable deployment mechanism, features that significantly enhance its usability during procedures.

The Myval Octapro THV is available in a wide range of sizes, including conventional, intermediate, and extra-large diameters. This variety allows for tailored bioprosthetic valve sizing for each patient, an important factor for healthcare providers aiming for optimal results. Supported by extensive clinical evidence, this device is designed to make a real-life impact on patient care.

Clinical Evidence and Global Collaboration

The efficacy of the Myval THV series has been substantiated through the LANDMARK RCT (Randomized Controlled Trial), which was published in The Lancet in 2024. This study, led by renowned clinicians across 31 centers in 16 countries, involved a total of 768 patients. Notable findings demonstrated that the Myval THV series is not inferior to contemporary TAVR systems, with significantly better effective orifice area (EOA) for valve sizes of 23, 26, and 29 mm compared to balloon-expandable technologies.

Interestingly, nearly half of the Myval THV implants were of intermediate size, a unique offering that sets this series apart from current TAVR technologies. These advancements position Meril as a pioneer in addressing unmet clinical needs, underscoring the organization’s commitment to ongoing research and development.

Navigating Challenges and Future Commitments

Despite its innovative strides, Meril faces challenges such as the recent decision by the Unified Patent Court (UPC) to impose restrictions on the sale of its Myval Octacor THV in certain EU member states. While respecting the legal process, Meril remains firm in its belief in the value and integrity of its technology and has committed to appealing the decision.

Historically, Meril has successfully challenged similar patent issues in various jurisdictions, demonstrating resilience in defending its innovations. This perseverance highlights the company's unwavering commitment to providing top-tier TAVR solutions, which are recognized and lauded by the global clinical community.

Looking Ahead

Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, stated, "Our commitment to developing world-class TAVR solutions remains unshakeable. We are dedicated to ensuring that through the Myval Octapro THV, both physicians and patients around the globe will continue to benefit from advanced cardiovascular technologies."

Meril extends its gratitude to the healthcare professionals, distribution partners, and patients who share its vision for innovative cardiac solutions. As the company forges ahead, its focus on clinical research and future development remains pivotal in alleviating human suffering and enhancing the quality of life for those impacted by severe aortic stenosis and related health issues.

For more information about Meril's products and technological advancements, please visit www.merillife.com.